Pacer Advisors Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Pacer Advisors Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 397,666 shares of the biopharmaceutical company’s stock after selling 47,659 shares during the quarter. Pacer Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $306,946,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $1,012,296,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. Nuveen LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the last quarter. Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Regeneron Pharmaceuticals by 8,620.0% during the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.3%

REGN stock opened at $609.94 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $506.38 and a twelve month high of $821.11. The company has a market cap of $64.48 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. The business’s 50-day simple moving average is $680.12 and its 200 day simple moving average is $733.15. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the business posted $8.22 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Analyst Upgrades and Downgrades

Several brokerages have commented on REGN. Cantor Fitzgerald restated an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Barclays lowered their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Finally, Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $900.00 to $700.00 in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.